Natco Pharma releases Hepatitis C drug in India

July 03, 2018 | Tuesday | News

The product is a generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg tablets.

Image credit- npr.org

Image credit- npr.org

Fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C under the brand name Hepcinat Plus, has been launched by Natco Pharma in India. 

The product is a generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg tablets, used for the treatment of patients with chronic Hepatitis C virus (HCV) infection 

The company has launched the drug at a maximum retail price of Rs 17,500 for a bottle of 28 tablets. 

 
 

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy